Literature DB >> 9180392

Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.

E Raymond1, A Hanauske, S Faivre, E Izbicka, G Clark, E K Rowinsky, D D Von Hoff.   

Abstract

Paclitaxel shows a broad clinical activity in ovarian, breast and non-small cell lung cancers. However, controversy remains about the respective effects of doses and schedules in paclitaxel cytotoxicity. This study was conducted to compare the cytotoxic activity of short-term (1 h) versus prolonged exposure (14 days) to paclitaxel in human cancer cells. A soft-agar cloning system assay was used to determine the in vitro effects of 0.025-25.0 microg/ml paclitaxel against cancer cells taken directly from patients. A decrease in tumor colony formation resulting from drug exposure was considered an in vitro response if survival of colonies was up to 50% of that in positive controls. Among 11 evaluable patients' biopsies, both short- and long-term exposure to paclitaxel had significant concentration-dependent effects on the growth inhibition of human cancer cells. With the 1 h exposure schedule, in vitro responses were observed in 9,18 and 64% of evaluable tumor specimens at final concentrations of 0.25, 2.5 and 25.0 microg/ml, respectively. With the prolonged exposure schedule, concentrations of 0.25, 2.5 and 25.0 microg/ml induced 27, 45 and 91 in vitro response rates, respectively. In those patients' biopsies prolonged exposure to paclitaxel induced significantly more in vitro tumor responses than 1 h administration (p < 0.01). Similar trends were observed in ovarian, breast and non-small cell lung cancers. Our data indicate that the duration of exposure to paclitaxel is an important factor in paclitaxel cytotoxicity in human tumors and suggest that long-term exposure may improve the antitumor activity of paclitaxel.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180392     DOI: 10.1097/00001813-199704000-00011

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  10 in total

1.  In Vitro and In Vivo Efficacy of Self-Assembling RGD Peptide Amphiphiles for Targeted Delivery of Paclitaxel.

Authors:  Poonam Saraf; Xiaoling Li; Lisa Wrischnik; Bhaskara Jasti
Journal:  Pharm Res       Date:  2015-06-11       Impact factor: 4.200

2.  Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel.

Authors:  Jingwei Xie; Chi-Hwa Wang
Journal:  Pharm Res       Date:  2005-09-03       Impact factor: 4.200

3.  In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.

Authors:  R A Schwendener; K Friedl; H Depenbrock; H Schott; A R Hanauske
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

4.  Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression.

Authors:  Leticia Medina-Gundrum; Cesario Cerna; Lionel Gomez; Elzbieta Izbicka
Journal:  Invest New Drugs       Date:  2005-01       Impact factor: 3.850

5.  Combination chemotherapy in the treatment of inoperable non-small cell lung cancer.

Authors:  R M Rutherford; T Azher; J J Gilmartin
Journal:  Ir J Med Sci       Date:  2002 Oct-Dec       Impact factor: 1.568

6.  Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).

Authors:  James I Geller; Donna Wall; John Perentesis; Susan M Blaney; Mark Bernstein
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

7.  Nanoparticles of Poly(Lactide-Co-Glycolide)-d-a-Tocopheryl Polyethylene Glycol 1000 Succinate Random Copolymer for Cancer Treatment.

Authors:  Yuandong Ma; Yi Zheng; Kexin Liu; Ge Tian; Yan Tian; Lei Xu; Fei Yan; Laiqiang Huang; Lin Mei
Journal:  Nanoscale Res Lett       Date:  2010-05-06       Impact factor: 4.703

8.  Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy.

Authors:  Hima Bindu Ruttala; Young Tag Ko
Journal:  Pharm Res       Date:  2014-09-12       Impact factor: 4.200

9.  Thermoreversible Pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies.

Authors:  Shufang Nie; W L Wendy Hsiao; Weisan Pan; Zhijun Yang
Journal:  Int J Nanomedicine       Date:  2011-01-19

10.  A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.

Authors:  Min-Hee Ryu; Baek-Yeol Ryoo; Tae Won Kim; Sung Bae Kim; Hyeong-Seok Lim; Kyun-Seop Bae; Sook Ryun Park; Yeong-Woo Jo; Hyun Ju Cho; Yoon-Koo Kang
Journal:  Oncologist       Date:  2017-02-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.